Stay updated on Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial
Sign up to get notified when there's something new on the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page.

Latest updates to the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; this minor version change does not affect page content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedAdded a Locations section with a Texas site; removed the Texas Locations section and the HHS Vulnerability Disclosure link, and updated the revision to v3.3.3.SummaryDifference0.2%

- Check54 days agoChange DetectedAn editorial note was added that publications are automatically filled from PubMed, and the page revision was updated to v3.3.2. The previous wording about PubMed publications and automatic listing by ClinicalTrials.gov was removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check61 days agoChange DetectedThe government funding/operation status notice has been removed from the page, leaving the focus on the study details and related information.SummaryDifference0.3%

- Check75 days agoChange DetectedNo significant changes were detected. The Study Details page remains the same in content and layout.SummaryDifference0.3%

- Check104 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference2%

Stay in the know with updates to Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page.